A5058248180- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- RNA modifications and cancer
- Immune Cell Function and Interaction
- Ferroptosis and cancer prognosis
- Cancer-related molecular mechanisms research
- Breast Cancer Treatment Studies
- Lung Cancer Research Studies
- Melanoma and MAPK Pathways
- PI3K/AKT/mTOR signaling in cancer
- Cancer Immunotherapy and Biomarkers
- Ultrasound and Hyperthermia Applications
- Gastrointestinal Tumor Research and Treatment
- Lymphoma Diagnosis and Treatment
- DNA Repair Mechanisms
Cancer Research UK Manchester Institute
2007-2025
CRUK Lung Cancer Centre of Excellence
2022-2023
University of Manchester
2022-2023
Cancer Research UK
2022-2023
AstraZeneca (United Kingdom)
2016-2018
AstraZeneca (Brazil)
2016
This study investigates the association of PD-L1 expression and immune cell infiltrates their impact on clinical outcome, in addition to overlap with microsatellite instability (MSI), HER2 ATM molecular subgroups gastric cancer (GC). membrane tumour cells (TC) infiltrating (IC), CD3 + T-lymphocytes, CD8+ cytotoxic T-cells, were assessed by immunohistochemistry (IHC) ACRG (Asian Cancer Research Group) GC cohort (N = 380). EBV status was determined using situ hybridization MSI performed PCR...
Abstract Tractable, patient-relevant models are needed to investigate cancer progression and heterogeneity. Here, we report an alternative in vitro model of lung squamous cell carcinoma (LUSC) using primary human bronchial epithelial cells (hBECs) from three healthy donors. The co-operation ubiquitous alterations ( TP53 CDKN2A loss) components commonly deregulated pathways including differentiation SOX2 ), PI3K signalling PTEN ) the oxidative stress response KEAP1 is investigated by...
Lung squamous cell carcinoma (LUSC) is a type of lung cancer with dismal prognosis that lacks adequate therapies and actionable targets. This disease characterized by sequence low- high-grade preinvasive stages increasing probability malignant progression. Increasing our knowledge about the biology these premalignant lesions (PMLs) necessary to design new methods early detection prevention, identify molecular processes are key for To facilitate this research, we have designed XTABLE (E x...
Abstract Tractable, patient relevant models are needed to investigate the essential components of normal cell transformation. We developed a unique in vitro model early lung squamous carcinoma (LUSC) genetic alterations and driver pathway dysregulation using genetically modified primary human bronchial basal cells (hBCs) from three independent donors. The co-operation ubiquitous LUSC (TP53 CDKN2A loss) commonly deregulated pathways including differentiation (SOX2), PI3K signaling (PTEN)...
ABSTRACT Tractable, patient relevant models are needed to investigate cancer progression and heterogeneity. Here, we report an alternative unique in vitro model of lung squamous cell carcinoma (LUSC) using primary human bronchial epithelial cells (hBECs) from three healthy donors. The co-operation ubiquitous alterations ( TP53 CDKN2A loss) components commonly deregulated pathways including differentiation SOX2 ), PI3K signalling PTEN ) the oxidative stress response KEAP1 was investigated by...
ABSTRACT Lung squamous cell carcinoma (LUSC) is a type of lung cancer with dismal prognosis that lacks adequate therapies and actionable targets. This disease characterized by sequence low high-grade preinvasive stages increasing probability malignant progression. Increasing our knowledge about the biology these premalignant lesions (PMLs) necessary to design new methods early detection prevention, identify molecular processes are key for To facilitate this research, we have designed XTABLE,...
Abstract Background: Lung squamous cell carcinoma (LUSC) arises from the accumulation of genetic driver alterations in bronchial basal cells. LUSC genomes lack obvious actionable mutations and present with a high degree inter-tumor heterogeneity. Tractable, patient relevant models are needed to study pathogenesis investigate role recurrent genomic driving cancer progression. Therefore, we developing tractable human model progression increase our understanding this disease. Methods: To...